

Drug–drug interactions between bedaquiline and the
and nevirapine in HIV-infected patients with drug-resis

Journal of Antimicrobial Chemotherapy

71, 1037-1040

DOI: [10.1093/jac/dkv447](https://doi.org/10.1093/jac/dkv447)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Selected questions and controversies about bedaquiline: a view from the field. International Journal of Tuberculosis and Lung Disease, 2016, 20, 24-32.	0.6	8
2	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Review of Clinical Pharmacology, 2016, 9, 1025-1037.	1.3	19
3	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine, 2017, 5, 291-360.	5.2	459
4	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. European Respiratory Journal, 2017, 49, 1700146.	3.1	59
5	Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 212-217.	1.1	38
6	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1300-1310.	2.5	61
7	Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. Journal of Antimicrobial Chemotherapy, 2017, 72, 338-353.	1.3	103
8	Drugs Used in TB and Leprosy. Side Effects of Drugs Annual, 2017, , 283-293.	0.6	7
9	Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update. Current Treatment Options in Infectious Diseases, 2018, 10, 90-106.	0.8	0
10	Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 59-82.	1.5	36
11	Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clinical Infectious Diseases, 2018, 66, 1625-1630.	2.9	131
12	Recent controversies about <scp>MDR</scp> and <scp>XDR</scp> TB: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDR</scp> TB regimen and bedaquiline for all with <scp>MDR</scp> TB?. Respiriology, 2018, 23, 36-45.	1.3	52
13	Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. Journal of Thoracic Disease, 2018, 10, 3102-3118.	0.6	34
14	Challenges of TB and HIV co-treatment. Current Opinion in HIV and AIDS, 2018, 13, 486-491.	1.5	31
15	Treatment of drug-resistant tuberculosis among people living with HIV. Current Opinion in HIV and AIDS, 2018, 13, 478-485.	1.5	13
16	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology, 2018, 84, 2384-2392.	1.1	23
17	Universal Health Coverage in Africa: Coinfections and Comorbidities. Trends in Parasitology, 2018, 34, 813-817.	1.5	3
18	Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 26-29.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study. PLoS ONE, 2018, 13, e0193491.	1.1	20
20	Management of patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 645-662.	0.6	55
21	Management of drug-resistant tuberculosis. Lancet, The, 2019, 394, 953-966.	6.3	186
22	Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian Journal of Pediatrics, 2019, 86, 725-731.	0.3	4
23	Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1112, 48-55.	1.2	14
25	Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opinion on Drug Safety, 2020, 19, 23-41.	1.0	24
26	COVID-19 -Tuberculosis interactions: When dark forces collide. Indian Journal of Tuberculosis, 2020, 67, S155-S162.	0.3	47
27	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 3433-3457.	1.3	23
28	Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundamental and Clinical Pharmacology, 2020, 34, 530-547.	1.0	33
29	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	3.1	89
30	On-ward participation of clinical pharmacists in a Chinese intensive care unit for patients with COVID-19: A retrospective, observational study. Research in Social and Administrative Pharmacy, 2021, 17, 1853-1858.	1.5	14
31	Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis. Expert Opinion on Pharmacotherapy, 2021, 22, 535-541.	0.9	2
32	Tuberculosis and pharmacological interactions: A narrative review. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100007.	1.7	11
33	Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clinical Infectious Diseases, 2021, 73, 2083-2092.	2.9	24
34	Bedaquiline: Current status and future perspectives. Journal of Global Antimicrobial Resistance, 2021, 25, 48-59.	0.9	43
35	A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report. International Journal of Infectious Diseases, 2021, 107, 176-178.	1.5	6
36	Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. Drug Metabolism Reviews, 2019, 51, 76-90.	1.5	10
37	Tuberculosis - Present Medication and Therapeutic Prospects. Current Medicinal Chemistry, 2020, 27, 630-656.	1.2	2

#	ARTICLE	IF	CITATIONS
38	Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations. , 2019, , 239-267.		0
39	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. Journal of Infectious Diseases, 2022, 226, 147-156.	1.9	8
40	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1772-1780.	2.9	8
41	Treatment of Tuberculosis and the Drug Interactions Associated With HIV-TB Co-Infection Treatment. Frontiers in Tropical Diseases, 2022, 3, .	0.5	5
42	FOLLOW UP CASES OF BEDAQUILINE IN XDR-TB PATIENTS: NOVEL CASE SERIES. , 2022, , 76-78.		0